US Top Rating Updates on 10/18: ABT, MDT, DXCM, XYL and More

Cowen analyst Joseph Giordano upgraded $Xylem(XYL.US)$ to Outperform from Market Perform with a price target of $105, up from $85. Survey work suggests municipal budget expansion at least through fiscal 2023 and utility interviews highlight Xylem as well positioned to lead in smart infrastructure, where backlogs are significant and will pace 2023 revenue growth, Giordano tells investors in a research note.

Barclays analyst Raimo Lenschow downgraded $UiPath(PATH.US)$ to Equal Weight from Overweight with a price target of $15, down from $17. UiPath is in a "digestive phase" from leadership changes and its go-to-market restructuring that will prevent it from being a significant outperformer in the near-term, Lenschow tells investors in a research note.

Goldman Sachs analyst Neil Mehta upgraded $EOG Resources(EOG.US)$ to Buy from Neutral with a price target of $143, up from $125. The analyst believes the shares are not factoring in the upside from "modest" growth and improving cost positioning of the company's resource base following strong capex execution.